Patents Assigned to Elanco Tiergesundheit AG
  • Patent number: 11938103
    Abstract: The present invention provides a method of treating liver fluke infections in a mammal in need of such treatment comprising administering an effective amount of diamphenethide in combination with an effective amount of clorsulon.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: March 26, 2024
    Assignee: Elanco Tiergesundheit AG
    Inventors: Sarah George, Peter Rolfe, Chouaib Tahtaoui
  • Patent number: 11904008
    Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: February 20, 2024
    Assignee: Elanco Tiergesundheit AG
    Inventors: Klaus Linde, Anke Grosse-Herrenthey
  • Patent number: 11319377
    Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 3, 2022
    Assignee: ELANCO TIERGESUNDHEIT AG
    Inventors: Sarah Rue, Brendan Eckelman, Quinn L. Deveraux, Marc Nasoff
  • Patent number: 10981897
    Abstract: The present invention provides compounds of the formula: (I) wherein: X is O or S; Q1 and Q2 are independently CR5 or N, provided at least one of Q1 and Q2 is N; Y is a direct bond or CH2; R1 is H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, benzyl or oxetan-3-yl-CH2—; R2 is optionally substituted phenyl, pyridine, pyrimidine, pyrazine or pyridazine; R3 is alkyl or haloalkyl; R4 is optionally substituted pyridine, pyrimidine, pyrazine or pyridazine; R5 is H, alkyl, haloalkyl, cycloalkyl, alkoxy, alkoxyC(O)— or (alkoxy)2CH—; or a salt thereof. The compounds are useful for controlling ectoparasites on animals.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 20, 2021
    Assignee: Elanco Tiergesundheit AG
    Inventors: Paolo Tosatti, Jean-Yves Wach
  • Patent number: 10874618
    Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 29, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
  • Patent number: 10828362
    Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: November 10, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Klaus Linde, Anke Grosse-Herrenthey
  • Patent number: 10537549
    Abstract: The present invention provides a dihydroisoxazole of formula: or a salt thereof, for use in the control of sea lice in fish.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 21, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventor: Chouaib Tahtaoui
  • Patent number: 10464889
    Abstract: The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: November 5, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui
  • Patent number: 10370375
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: August 6, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • Patent number: 10287276
    Abstract: The present invention provides compounds of the formula: (I) wherein: X is O or S; Q1 and Q2 are independently CR5 or N, provided at least one of Q1 and Q2 is N; Y is a direct bond or CH2; R1 is H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, benzyl or oxetan-3-yl-CH2—; R2 is optionally substituted phenyl, pyridine, pyrimidine, pyrazine or pyridazine; R3 is alkyl or haloalkyl; R4 is optionally substituted pyridine, pyrimidine, pyrazine or pyridazine; R5 is H, alkyl, haloalkyl, cycloalkyl, alkoxy, alkoxyC(O)— or (alkoxy)2CH—; or a salt thereof. The compounds are useful for controlling ectoparasites on animals.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 14, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Paolo Tosatti, Jean-Yves Wach
  • Patent number: 10261092
    Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 16, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
  • Patent number: 10059709
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: August 28, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • Patent number: 10047040
    Abstract: The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: August 14, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui
  • Patent number: 10040785
    Abstract: The present invention concerns compounds of formula (I) or an N-oxide or salt thereof and their use for controlling parasites in and on warm-blooded animals or fish.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: August 7, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noëlle Gauvry, Thomas Goebel, Steve Nanchen, Jean-Luc Perret, Ulrich Roos, Sandra Schorderet Weber
  • Patent number: 10030232
    Abstract: Disclosed are methods for production of inactivated rotavirus directly from cell culture supernatants containing active or infectious rotavirus (e.g., bovine rotavirus), without prior isolation or purification of the rotavirus from the cell culture supernatants. In some embodiments, inactivated rotavirus (e.g., bovine rotavirus) is produced by heating a volume of culture supernatant to at least a temperature at which the rotavirus is inactivated. In some embodiments, the rotavirus (e.g., bovine rotavirus) is inactivated once the entire volume is heated to at least a temperature at which the rotavirus is inactivated. In some embodiments, the temperature of the cell culture supernatant is maintained for a suitable amount of time, which may be determined using any of the tests described herein. Inactivated rotavirus (e.g., bovine rotavirus) may then be isolated from the culture supernatant.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: July 24, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Brent E. Dekker, John M. Herbert, Michael J. Reimnitz
  • Patent number: 9920037
    Abstract: The present invention concerns compounds of formula (I) or an N-oxide or salt thereof and their use for controlling parasites in and on warm-blooded animals or fish.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 20, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noëlle Gauvry, Thomas Goebel, Steve Nanchen, Jean-Luc Perret, Ulrich Roos, Sandra Schorderet Weber
  • Patent number: 9884103
    Abstract: Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 6, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Juan Jose Borrego, Carlos Carballo Perez, Maria Del Carmen Alonso, Esther Garcia Rosado, Benjamin Lopez-Jimena, Jose F Rodriguez
  • Patent number: 9820488
    Abstract: The invention relates to compounds of the general formula (I) wherein the variable have the meanings as indicated in the claims, or a physiologically acceptable salt thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling endoparasites in warm-blooded animals.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: November 21, 2017
    Assignee: ELANCO TIERGESUNDHEIT AG
    Inventors: Noëlle Gauvry, François Pautrat
  • Patent number: 9809863
    Abstract: This disclosure relates to Theiler's disease-associated virus (“TDAV”), reagents relating thereto, and methods for detecting, using, and/or treating diseases associated with TDAV.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: November 7, 2017
    Assignees: ELANCO TIERGESUNDHEIT AG, CORNELL UNIVERSITY
    Inventors: Sanjay Chandriani, Peter Skewes-Cox, Amy Kistler, Bud Tennant, Thomas Divers
  • Patent number: 9790280
    Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: October 17, 2017
    Assignee: Elanco Tiergesundheit AG
    Inventors: Sarah Rue, Brendan Eckelman, Quinn Deveraux, Marc Nasoff